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ABSTRACT
Objective: Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder characterized by rest tremors, bradykinesia, rigidity, 
postural instability, gait dysfunction, and several non-motor symptoms. The marked difference in drug response and adverse effect profile among 
patients led to search of genetic markers and polymorphism associated with response to antiparkinsonian drugs which will enable us to predict 
an individual’s response to drugs in terms of both efficacy and toxicity. Hence, efforts to define the role of genetic polymorphism in optimizing 
pharmacotherapy of PD have been undertaken and some promising genetic loci for the treatment have been determined. Therefore, we aim to present 
a critical review of pharmacogenetic aspects of levodopa, dopamine agonists (DAs), and catecol-O-methyltransferase (COMT) inhibitors and describe 
gene polymorphism of interest for future research.
Methods: The PubMed database was searched using the keywords “parkinsonism,” “antiparkinsonian drugs,” “levodopa,” “DAs,” “COMT inhibitors,” 
“pharmacogenomics,” and “polymorphism.” Abstracts and review articles were included for the study.
Results and Conclusion: Studies conducted in different settings suggest that pharmacogenomics plays a significant role in Parkinsonism drug 
therapy. The gene/drug pairings with the strongest potential for pharmacogenetic recommendations include COMT allele/levodopa and entacapone, 
dopamine D2 receptor (DRD2)/ropinirole, pramipexole, and DRD3/ropinirole and pramipexole. It can be concluded that with the rapid development 
of genotyping platforms, genome-wide association study can be performed to analyze polymorphism associated with inefficient treatment or adverse 
effects. Hence, individualized therapy of PD for better patient care can be achieved by targeted genetic testing.
Keywords: Parkinson’s disease, Catecol-O-methyltransferase inhibitors, Levodopa, Pharmacogenomics.
INTRODUCTION
Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder with increasing evidence of genetic factor contributing to its 
etiology. Availability of effective pharmacological therapy distinguishes 
it from other neurodegenerative disorders. The nigrostriatal 
dopaminergic pathway is the target for most of the available 
therapies [1].
For symptomatic relief L-dopa in combination with carbidopa is the 
drug of choice apart from which dopamine agonists (DAs), catecol-
O-methyltransferase (COMT) inhibitors and monoamine oxidase 
inhibitors are the other drugs available. The marked difference in 
drug response and adverse effect profile among patients led to search 
of genetic markers and polymorphism associated with response to 
antiparkinsonian drugs which will enable us to predict an individual’s 
response to drugs in terms of both efficacy and toxicity. Currently 
available drugs that target only the motor symptoms are ineffective lose 
over time and can cause catastrophic adverse effects. This variation in 
interindividual drug therapy has increased the need of personalized 
medicine and hence pharmacogenetic analysis of variations in drug 
response.
Pharmacogenomics is defined as the study of the genetic basis of 
drugs and drug therapy outcomes. Efficacy and toxicity are the two 
categories of treatment outcomes. Response to the same drug can vary 
among individuals, and significant differences are observed among 
individuals belonging to the same population as compared to within 
the same individual at different times [2]. About 20-95% of variations 
in drug pharmacokinetics and effects are estimated to be due to genetic 
factors. However, variation in genetic codes of drug metabolizing 
enzymes, transporters and receptors can also lead to interindividual 
variations [3]. An important aim of pharmacogenomics is to develop 
drugs with maximum efficacy with minimum toxicity by rationalized 
drug therapy [4]. “Personalized medicine” an upcoming concept, 
holds promise in that drugs and drug combinations are optimized 
for the genetic makeup of the individual [5]. Pharmacogenomics has 
wide applications in several diseases such as cardiovascular disease, 
psychosomatic and neurodegenerative disorders, chronic infectious 
diseases, metabolic disorders, and obstructive diseases of respiratory 
system.
Pharmacogenomics has the potential to change the way new drugs 
are developed, and the manner drugs are prescribed [6] via the 
use of genetic markers the drug response, its efficacy and potency 
can be predicted. Clinical trials will be designed to be enriched with 
individuals that are most in all likelihood to be benefitted by the drug, 
maximizing drug’s efficacy, minimizing its unfavorable outcomes, and 
boosting the odds of successful discovery of drugs. Pharmacogenomics 
applied clinically will help physicians to accurately determine the 
right drugs, the right doses for right individuals [6]. It enables to avoid 
tedious trial and blunders approaches and keep away from detrimental 
impact consequently enhancing the patient compliance and improving 
the effectiveness of the therapy as well. Relatively, few efforts have 
been made to investigate the role of pharmacogenetics in anti-PD 
drug to evaluate individual response. Hence, many genetic variations 
and polymorphisms in a myriad of different proteins can affect person 
response to anti-PD drugs. Hence, we aim to present a critical review 
of the pharmacogenetic aspects of antiparkinsonian drug therapy and 
identify gene polymorphisms of interest for future research.
PHARMACOGENOMICS AND PD
Research performed in extraordinary settings propose that 
pharmacogenomics plays a widespread position in parkinsonism drug 
therapy. The gene/drug pairings with the most powerful capability 
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for pharmacogenetic guidelines include: COMT allele/levodopa and 
entacapone, dopamine D2 receptor (DRD2)/ropinirole, pramipexole, 
and DRD3/ropinirole and pramipexole.
TARGETS OF ANTIPARKINSONIAN TREATMENT
Dopamine receptors (DRDs)
PD is the most recognized dopamine-related disorder, which originates 
from a loss of dopaminergic innervations in the brain. The physiological 
actions of dopamine are mediated by five different but intently related 
G protein-coupled receptors. The two major groups of which include: 
The D1 and D2 classes of DRDs [7]. Genetic cloning approaches later 
revealed that multiple receptor subtypes can be activated by dopamine. 
Based on structural, pharmacological, and biochemical properties, 
these receptors were classified as either D1-class DRDs (D1 and D5) or 
D2-class DRDs (D2, D3, and D4).
The individual members of the subfamilies of the D1- and D2-class 
receptors share an extensive level of homology of their transmembrane 
domains and feature distinct pharmacological properties. D1-class DRDs 
(D1 and D5) activates the Gαs/olf family of G proteins to stimulate 
cyclic adenosine monophosphate formation using adenylcyclase. The 
D2-class DRDs couple to the Gαi/o of G proteins and therefore result in 
inhibition of adenyl cyclase. Relative to the D1-class DRDs, D2, and D3 
DRDs are expressed both postsynaptically on dopamine target cells and 
presynaptically on dopaminergic neurons [8].
The DRD1 and DRD2 are also extraordinary at the extent of genetic 
structure, typically inside the presence of introns in their coding 
sequences. The DRD1 and DRD5 genes do not comprise introns in their 
coding regions, however, the genes that encode the D2-class receptors 
have several introns, with six introns located in the gene that encodes 
the D2 dopamine receptor, 5 within the gene for the D3 dopamine 
receptor, and 3 in the gene for the DRD4 [9].
GENE LOCATION AND ASSOCIATED POLYMORPHISM
• The DRD1 gene is located on chromosome 5 and suggests 
numerous polymorphic loci that can modulate its feature like TaqIA 
polymorphism [10].
• The DRD2 gene encodes two isoforms with distinct functions, 
i.e., long (D2L) and short (D2S). It is located on chromosome 11. 
Numerous polymorphisms in DRD2 gene were discovered. The 
TaqIA polymorphism is related to decreased the range of striatal 
DRD2 receptor density in A1 allele carriers and any other recognized 
polymorphism in DRD2 gene constitutes of repeat CA, DRD2 (CA)n, 
and is positioned in a non-coding location of the gene [11].
• The DRD3 gene is positioned on chromosome 3. Maximum 
investigated polymorphisms consist of Ser9Gly (or MscI or BalI), 
which may additionally affect DRD3 receptor membrane insertion, 
and its intracellular reaction [12]. DRD3 (rs6280) polymorphism has 
also been known to influence the age of onset in ethnic groups [13].
• The DRD4 gene is located on chromosome 11 and shows Variable 
number tandem repeats (VNTR) polymorphism inside 3rd exon of 
2-11 repeats of 48 bp, likely modulating G-protein binding [14].
• The DRD5 gene is located on chromosome 4 and its polymorphism 
might also, because of its similar shape and feature to DRD1, mediate 
antiparkinsonian drug actions.
Dopamine active transporter (DAT)
Uptake of dopamine into neurons is mediated by DAT. It is the main target 
for numerous pharmacologically active substances and environmental 
pollutants. The DA transporter 1 gene (DAT1, additionally referred to as 
SLC6A3) is a membrane-spanning protein that mediates the reuptake 
of dopamine from the synapse [15]. DAT1 is the number one regulator 
of dopamine neurotransmission and is expressed inside the central 
nervous system, primarily in areas that make up the dopaminergic 
circuits (e.g., striatum and nucleus accumbens). DAT1 carries variable 
variety tandem repeats (VNTRs), places within the genome in which 
a quick nucleotide series is repeated a number of instances. Special 
individuals may have an exclusive variety of repeats, which can cause 
the gene to behave otherwise (e.g., produce more or less protein).
DAT gene (SLC6A3) is positioned on chromosome 5. A 40 bp variable 
range tandem repeats (VNTR) polymorphism within the 3’UTR was 
identified, and might have an effect on gene expression, accordingly 
dopamine uptake from the synaptic cleft. 40-bp VNTR of the DAT is a 
predictor for the incidence of psychosis or dyskinesia in L-dopa-treated 
patients [16].
COMT
The transfer of a methyl group from S-adenosylmethionine to 
catecholamines is catalyzed by COMT. This O-methylation results in one 
of the primary degradative pathways of the catecholamine transmitters. 
In addition to its position in the metabolism of endogenous materials, 
COMT is important in the metabolism of catechol drugs used within the 
remedy of hypertension, allergies, and PD. COMT is located in different 
forms in tissues, a soluble COMT (S-COMT) form, and a membrane-sure 
(MB-COMT) form. The differences among S-COMT and MB-COMT are 
inside the N-termini. Several transcript editions are shaped via the 
usage of opportunity translation initiation sites and promoters.
GENE LOCATION AND POLYMORPHISM
• Gene coding for COMT is placed on chromosome 22. The G to A 
transition at codon 158 (Val158Met; [rs4680]) is the most generally 
studied COMT polymorphism. This results in the substitution of 
methionine for valine, and become to start with related to low enzyme 
activity (COMT-L) because of its thermo liability, opposite to H (high 
activity) allele [17].
• COMT haplotypes describe enzymatic activity significantly. The three 
maximum not unusual haplotypes are composed of four COMT SNPs 
combinations: One in the S-COMT promoter region and in the S- and 
MB-COMT - two synonymous change (rs4633:C>T, His62His) and 
(rs4818: C>G, Leu136Leu) in addition to one non-synonymous trade 
(rs4680:A>G, Val158Met) [17].
HOMER1
This gene encodes a member of the homer family of dendritic 
proteins. Contributors of this family alter institution 1 metabotropic 
glutamate receptor characteristics. It’s miles a protein with the pivotal 
characteristic in glutamate transmission, which has been associated 
with the pathogenesis of levodopa-associated adverse drug effects.
ORGANIC CATION TRANSPORTER (OCT)
OCTs are involved inside the carriage of each endogenous compounds, 
together with dopamine, and drugs, like metformin and a few 
antiparkinsonian drugs. The three maximum important members of the 
OCT own family are OCT1, OCT2, and OCT3, encoded via the SLC22A1, 
SLC22A2, and SLC22A3 genes, respectively. Levodopa is a substrate 
for OCT, but the subtype is not always recognized. Pramipexole and 
amantadine are substrates for OCT1 and OCT2.
PHARMACOGENETIC CRITERIA OF THE TREATMENT
Levodopa
L-dopa is the best drug in the alleviation of motor impairments in PD, 
and its effectiveness and tolerability notably stepped forward after an 
introduction of its combination with a dopa-decarboxylase inhibitor, 
either benserazide or carbidopa. 50% of PD patients dealt with l-dopa 
increase motor complications within 5 years after therapy initiation, 
and the threat yields 90% with the treatment longer than 10 years. 
However, a huge inter-person variability has been seen in PD patients 
with l-dopa therapy, both in terms of drug efficacy and toxicity, with the 
notable contribution of genetic factors, specifically in genes encoding 
drug receptors, metabolizing enzymes and intracellular signaling 
proteins.
The gene polymorphism affecting therapy is as shown in Table 1.
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COMT inhibitors
Inhibition of COMT with new era COMT inhibitors, entacapone 
(peripherally acting), and tolcapone (peripheral and centrally acting) 
are powerful adjuvant therapy in PD. The efficacy is assessed using 
their dose-dependent inhibition of COMT interest in erythrocytes 
and a substantial lower within the plasma levels of 3-O-methyldopa. 
Availability of levodopa in the brain is increased by increasing the 
elimination half-life and hence the duration of action. Clinically, 
the improved levodopa availability is seen as prolonged duration 
of dyskinesias in PD patients with end-of-dose fluctuations. Thus, 
COMT inhibitors are a beneficial adjunct to levodopa therapy in 
PD patients with end-of-dose fluctuations [21]. The following gene 
polymorphism shown in Table 2 affects the efficacy and adverse 
effects of the COMT inhibitors [17,18].
DAs
DAs exert their antiparkinsonian effects by acting directly on DRD and 
mimicking the endogenous neurotransmitter. There are two subclasses 
of DAs: Ergoline and non-ergoline agonists. Both of these subclasses 
target dopamine D2-type receptors. They were introduced as an 
adjunct to levodopa treatment in patients exhibiting fluctuating motor 
responses and dyskinesias associated with its chronic use. DAs have 
also been successfully used as monotherapy in de novo patients with 
the aim of delaying treatment with levodopa and therefore deferring 
the onset of complications [22].
The gene polymorphisms noted are as shown in Table 3 [23].
CONCLUSION
It can be concluded that with the rapid development of genotyping 
platforms, genome-wide association study can be performed to analyze 
polymorphism associated with inefficient treatment or adverse effects. 
Hence, individualized therapy of PD for better patient care can be 
achieved by targeted genetic testing.
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